Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 30, 2015
November 2015 PDF



 

Melanoma

Keytruda Shows Anti-Tumor Activity in Three Combinations and Phase III Trial

Merck presented three studies investigating the use of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with three other immunotherapies—epacadostat, Imlygic (talimogene laherparepvec), and ipilimumab—in patients with advanced melanoma.

Keytruda showed anti-tumor activity in all three combinations studied. The findings were featured in separate oral presentations at the International Congress of the Society for Melanoma Research, in San Francisco.

Additionally, updated data presented from a phase III study of Keytruda as a single agent showed superior overall response rates and progression free survival compared to ipilimumab in ipilimumab-naïve patients, with twice as many patients achieving PFS on Keytruda compared to ipilimumab.

 

Drugs and Targets

FDA Approves Ninlaro and Darzalex For the Treatment of Multiple Myeloma

FDA approved Ninlaro (ixazomib), developed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.

The approval was based on an improvement in progression- free survival in a multicenter, randomized, double-blind, placebo-controlled trial enrolling 722 patients with multiple myeloma who had received one to three prior lines of therapy. Patients were randomized in a 1:1 ratio to either the combination of ixazomib, lenalidomide and dexamethasone (n=360) or the combination of placebo, lenalidomide and dexamethasone (n=362). Patients continued treatment until disease progression or unacceptable toxicity.

     

    Lymphoma

    Lenalidomide-Rituximab Combination Shows Benefits in Mantle Cell Lymphoma

    A combination therapy lacking many of the debilitating effects of traditional cancer treatment effectively manages mantle cell lymphoma, shrinking the malignancy and inducing remissions in the majority of patients, according to new research from Weill Cornell Medicine.

    The phase II study demonstrated that lenalidomide, in combination with rituximab, provides an effective alternative to chemotherapy. More than 90 percent of patients in the small efficacy trial responded to the therapy, with their cancer shrinking by more than half, and two-thirds of that group had no evidence of detectable tumor growth after treatment.

       

      Glioblastoma

      ICT-107 Boosts Overall Survival by 10 Percent In Phase II Trial

       

      Childhood Cancer

      Researchers: All Pediatric Patients, Regardless of Family History, Could Benefit from Genomic Screening

       

      Cancer Genomics

      TCGA Researchers Identify 7 Subtypes of Prostate Cancer And 2 Drivers of Papillary RCC

       

      Lung Cancer

      FDA Requests Data from Clovis For Rociletinib NDA in NSCLC

       

      NCI CTEP-Approved Studies for the Month of November


      Copyright (c) 2016 The Cancer Letter Inc.

      Letter